Candel Therapeutics Inc. is a pioneering biotechnology company leveraging oncolytic virus technology to develop localized cancer therapies that target malignant cells while preserving healthy tissue. With a strong emphasis on enhancing anti-tumor immunity, Candel's diverse and innovative pipeline addresses the treatment challenges posed by various difficult-to-treat malignancies. Supported by a solid intellectual property portfolio and strategic partnerships with leading research institutions, Candel is strategically positioned to make significant advancements in oncology, aiming to transform cancer care and improve patient outcomes.
Data last updated: April 11, 2026 at 9:31 AM EDT
Get e-mail RSI alerts when Candel Therapeutics Inc enters oversold or overbought territory. Free forever.
Add Alert